Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth Hormone Adjuvant Therapy in ICSI for Poor Ovarian Reserve
NCT05602090Phase 3Unknown
- Sponsor
- Beni Suef University
- Start
- Feb 2022
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatotropin in Diminished Ovarian Reserve (DOR) (2 arms), sponsored by Beni Suef University. Primary endpoint: pregnancy rate at 1 month. Status: unknown.
02
Drugs
somatotropin
03
Conditions
Diminished Ovarian Reserve (DOR)
Beyond the preview
Go deeper on NCT05602090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05602090.